Journal: Cancer Cell International

Article Title: Chimeric Antigen Receptor (CAR)-NK92 cells effective against glioblastoma, breast- and pancreatic cancer in vitro and in a murine xenograft model of ovarian cancer

doi: 10.1186/s12935-025-03865-0

Figure Lengend Snippet: 2D and 3D model of cytotoxicity efficacy of CD44v6-CAR-NK92 against breast cancer: ( A ) Representative flow cytometric analysis of CD44v6 expression on the breast cancer cell lines MCF-7, HCC1937 and T47D. ( B-D ) Cytotoxicity assays showing the percent cytotoxicity of CD44v6-CAR-NK92 cells against breast cancer cell lines in the 2D model compared to Empty-CAR-NK92 cells at various effector-to-target ratios (E: T ratios) after 18 h of incubation ( E-G ) Cytotoxicity assays showing the percent cytotoxicity of CD44v6-CAR-NK92 cells against breast cancer cell lines in the 3D model compared to Empty-CAR-NK92 cells at various effector-to-target ratios (E: T ratios) after 24 h of incubation. The results represent n = 3–4 independent experiments performed in triplicate. Statistical significances are presented using two-way ANOVA and marked p < 0.05 = *, p < 0.01 = **, p < 0.001 = ***, p < 0.00001 = ****, and ns for non-significant p-values

Article Snippet: The glioblastoma cell lines U-138-MG (DSMZ, Germany) and U-251-MG (Sigma-Aldrich Chemie GmbH), breast cancer cell lines MCF-7, HCC1937, SKBR3 and T47D (DSMZ, Germany), the pancreatic cancer cell line PANC-1 (DSMZ, Germany), and the fibroblast cell line MRC5 (LGC Standards GmbH) were cultured in Roswell Park Memorial Institute (RPMI) 1640 medium (Gibco) supplemented with 10% heat inactivated Fetal Bovine Serum (hiFBS), 1% Penicillin-Streptomycin (PS), while the breast cancer cell line MDA-MB-231 (DSMZ, Germany) and the ovarian cancer cell line SKOV-3 (Merck, Germany) were cultured with Dulbecco’s Modified Eagle’s Medium (DMEM; Gibco) containing 10% hiFBS, 1% PS and 1% Non-Essential Amino Acid (NEAA; Gibco).

Techniques: Expressing, Incubation

Journal: Cancer Cell International

Article Title: Chimeric Antigen Receptor (CAR)-NK92 cells effective against glioblastoma, breast- and pancreatic cancer in vitro and in a murine xenograft model of ovarian cancer

doi: 10.1186/s12935-025-03865-0

Figure Lengend Snippet: Enzyme-linked immunosorbent assay (ELISA): ELISA used to analyze the release of IFN-γ by CD44v6-CAR-NK92 cells or Empty-CAR-NK92 cells in co-culture supernatants against ( A ) PANC-1:MRC5 MCTS and ( B ) HCC1937 MCTS. The results represent n = 3 independent experiments performed in triplicate. Statistical significances are presented using multiple t test and marked p < 0.05 = *, p < 0.01 = **, p < 0.001 = ***, p < 0.00001 = ****, and ns for non-significant p-values

Article Snippet: The glioblastoma cell lines U-138-MG (DSMZ, Germany) and U-251-MG (Sigma-Aldrich Chemie GmbH), breast cancer cell lines MCF-7, HCC1937, SKBR3 and T47D (DSMZ, Germany), the pancreatic cancer cell line PANC-1 (DSMZ, Germany), and the fibroblast cell line MRC5 (LGC Standards GmbH) were cultured in Roswell Park Memorial Institute (RPMI) 1640 medium (Gibco) supplemented with 10% heat inactivated Fetal Bovine Serum (hiFBS), 1% Penicillin-Streptomycin (PS), while the breast cancer cell line MDA-MB-231 (DSMZ, Germany) and the ovarian cancer cell line SKOV-3 (Merck, Germany) were cultured with Dulbecco’s Modified Eagle’s Medium (DMEM; Gibco) containing 10% hiFBS, 1% PS and 1% Non-Essential Amino Acid (NEAA; Gibco).

Techniques: Enzyme-linked Immunosorbent Assay, Co-Culture Assay

Journal: Breast Cancer : Targets and Therapy

Article Title: Multi-Omics Characterization of ABHD12 Across Pan-Cancer and Validation of Its Role in Promoting Proliferation and Metastasis in Breast Cancer

doi: 10.2147/BCTT.S554836

Figure Lengend Snippet: ABHD12 is highly expressed in breast cancer tissues and promotes the proliferative capacity of breast cancer cells. (A and B) WB experiments confirm the expression of ABHD12 protein in breast cancer tissues and adjacent normal breast tissues. (C and D) IHC experiments verify the expression and localization of ABHD12 in breast cancer tissues (cytoplasm). ( E ) RT-qPCR experiments confirm the expression of ABHD12 mRNA in normal breast cells and breast cancer cells. Verification of ABHD12 knockdown and overexpression efficiency at the mRNA level in (F) MDA-MB-231 cell line and ( G ) HCC-1937 cell line. ( H ) Verification of ABHD12 knockdown and overexpression protein efficiency at protein level in MDA-MB-231 and HCC-1937 cell line. ( I ) Colony formation assays and their quantitative analysis in ( J ) MDA-MB-231 and ( K ) HCC-1937 cell lines further validate the impact of ABHD12 on cell proliferation. CCK-8 experiments demonstrate the effects of different ABHD12 expression levels on the proliferative capacity of ( L ) MDA-MB-231 cell line and ( M ) HCC-1937 cell line. * p <0.05, ** p <0.01, *** p <0.001; ns indicates no statistical significance.

Article Snippet: HCC-1937 cells were cultured in HCC-1937 cell-specific medium (CM-0093, Procell, China) supplemented with RPMI-1640, 10% FBS, and 1% penicillin-streptomycin solution (dual antibiotics).

Techniques: Expressing, Quantitative RT-PCR, Knockdown, Over Expression, CCK-8 Assay

Journal: Breast Cancer : Targets and Therapy

Article Title: Multi-Omics Characterization of ABHD12 Across Pan-Cancer and Validation of Its Role in Promoting Proliferation and Metastasis in Breast Cancer

doi: 10.2147/BCTT.S554836

Figure Lengend Snippet: Overexpression of ABHD12 in breast cancer cell lines enhances the invasive and migratory capabilities of breast cancer cells and promotes tumor formation in mice. Scratch assays demonstrate the differential effects of varying ABHD12 expression levels on the migratory capacity of (A and B) MDA-MB-231 cell line and (C and D) HCC-1937 cell line. Transwell invasion and migration assays validate the impact of ABHD12 knockdown and overexpression on the invasive and migratory properties of ( E–G ) MDA-MB-231 cell line and ( H–J ) HCC-1937 cell line. ( K–N ) Animal experiments assess the effects of ABHD12 knockdown and overexpression on body weight and tumor mass/volume in NCG mice. * p <0.05, ** p <0.01, *** p <0.001.

Article Snippet: HCC-1937 cells were cultured in HCC-1937 cell-specific medium (CM-0093, Procell, China) supplemented with RPMI-1640, 10% FBS, and 1% penicillin-streptomycin solution (dual antibiotics).

Techniques: Over Expression, Expressing, Migration, Knockdown

Journal: Breast Cancer : Targets and Therapy

Article Title: Identification and Validation of a Novel Theranostic Target in Triple Negative Breast Cancer with Transcriptomics and Protein Analyses

doi: 10.2147/BCTT.S568001

Figure Lengend Snippet: Validation of LY6E expression in TNBC cell lines and xenograft tumors. ( A ) Western blot analysis of whole-cell lysates from HMEC and TNBC cell lines. LY6E was detected in MDA-MB-468, HCC-1143, and HCC-1937, and showed weak expression in HMEC. ( B ) Flow cytometry analysis of MDA-MB-468 cells confirmed membrane localization of LY6E (red) compared with isotype control (gray). ( C ) Immunofluorescence confocal microscopy of MDA-MB-468 cells showing LY6E staining (green) localized to the cell membrane. Nuclei were counterstained with DAPI (blue). ( D ) Western blot analysis of tumors derived from MDA-MB-468 xenografts demonstrating consistent LY6E expression.

Article Snippet: HCC-1143 and HCC-1937 cells were obtained from Korean Cell Line Bank (Seoul, Korea).

Techniques: Biomarker Discovery, Expressing, Western Blot, Flow Cytometry, Membrane, Control, Immunofluorescence, Confocal Microscopy, Staining, Derivative Assay